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Abstract 
Background: TDP-43 aggregates accumulate in individuals affected by amyotrophic lateral sclerosis (ALS) and other 
neurodegenerative diseases, representing potential diagnostic and therapeutic targets. Using an atomic force micros-
copy based biopanning protocol developed in our lab, we previously isolated 23 TDP-43 reactive antibody fragments 
with preference for human ALS brain tissue relative to frontotemporal dementia, a related neurodegeneration, and 
healthy samples from phage-displayed single chain antibody fragment (scFv) libraries. Here we further characterize 
the binding specificity of these different scFvs and identify which ones have promise for detecting ALS biomarkers in 
human brain tissue and plasma samples.
Results: We developed a sensitive capture ELISA for detection of different disease related TDP-43 variants using the 
scFvs identified from the ALS biopanning. We show that a wide variety of disease selective TDP-43 variants are present 
in ALS as the scFvs show different reactivity profiles amongst the ALS cases. When assaying individual human brain 
tissue cases, three scFvs (ALS-TDP6, ALS-TDP10 and ALS-TDP14) reacted with all the ALS cases and 12 others reacted 
with the majority of the ALS cases, and none of the scFvs reacted with any control samples. When assaying individual 
human plasma samples, 9 different scFvs reacted with all the sporadic ALS samples and again none of them reacted 
with any control samples. These 9 different scFvs had different patterns of reactivity with plasma samples obtained 
from chromosome 9 open reading frame 72 (c9orf72) cases indicating that these familial ALS genetic variants may 
display different TDP-43 pathology than sporadic ALS cases.
Conclusions: These results indicated that a range of disease specific TDP-43 variants are generated in ALS patients 
with different variants being generated in sporadic and familial cases. We show that a small panel of scFvs recognizing 
different TDP-43 variants can generate a neuropathological and plasma biomarker profile with potential to distinguish 
different TDP-43 pathologies.
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Background
The progressive loss of motor neurons in regions includ-
ing the spinal cord and cortex is a general occurrence 
in the advancement of the neurodegenerative disorder 
amyotrophic lateral sclerosis (ALS) [1–6]. Approximately 
1–2 individuals per 100,000 are affected by ALS per year 
with an average life expectancy of 3–5 years [7, 8]. ALS 
cases can be divided into sporadic and familial classifica-
tions with the vast majority of the cases in the sporadic 
category [7, 8]. Mutations in genes including superoxide 
dismutase 1 (SOD1) and chromosome 9 open reading 
frame 72 (C9ORF72) have been linked to familial ALS 
[5, 7, 8]. Alterations to normal expression or structure of 
TAR DNA-binding protein 43 (TDP-43) have been sug-
gested to play a major role in ALS, occurring in about 
97% of cases [1, 3–6, 9, 10]. Normally TDP-43 is predom-
inantly located in the cell nucleus where it participates 
as an important RNA/DNA binding protein involved in 
gene splicing and other RNA-related processes [5, 11]. 
However, during progression of ALS aggregates of TDP-
43 accumulate in the cell cytoplasm. Variations of TDP-
43 including ubiquitinated, truncated, phosphorylated 
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and oligomeric forms exist in ALS [5, 12–14]. Therefore, 
reagents that can selectively bind different disease related 
TDP-43 variants have potential diagnostic and therapeu-
tic applications for ALS.
An association between protein aggregation and dis-
ease development is also found in a number of other 
neurodegenerative disorders including Alzheimer’s (AD) 
and Parkinson’s (PD) diseases, where aggregates of beta-
amyloid and alpha-synuclein, respectively, have been 
identified [15–31]. We previously demonstrated that we 
could generate single-chain variable fragments (scFvs) 
that selectively recognize different oligomeric variants of 
beta-amyloid, and that these scFvs could readily distin-
guish between human AD and control brain tissue, cere-
brospinal fluid (CSF) and sera samples [28]. Similarly, we 
generated scFvs that selectively bind distinct oligomeric 
variants of alpha-synuclein, and demonstrated that these 
scFvs could readily distinguish between human PD and 
control brain tissue, CSF and sera samples [28]. These 
protein variant selective scFvs were isolated using an 
atomic force microscopy (AFM) based biopanning pro-
tocol [15, 20, 24–27]. The biopanning protocol utilizes 
a series of negative panning steps to remove phage par-
ticles that bind non-desired targets such as monomeric 
and fibrillar aggregates prior to completion of the positive 
panning step. This protocol was also utilized to generate 
scFvs against variants of TDP-43 present in human ALS 
cases (Stage 1A from Additional file 1: Fig. S1) [32]. We 
immunoprecipitated TDP-43 proteins from the homog-
enized motor cortex of ALS and control cases using a 
commercially available polyclonal anti-TDP-43 antibody 
as previously described [32]. Since TDP-43 pathology 
also exists in around 45% of frontotemporal dementia 
(FTD) cases [5, 33–37], we also included multiple rounds 
of negative panning against TDP-43 variants immuno-
precipitated from the motor cortex of FTD cases. After 
biopanning, we identified 23 different complete scFv 
sequences that all preferentially bound ALS tissue over 
both FTD and healthy samples using indirect phage ELI-
SAs (Stage 2 from Additional file 1: Fig. S1) [32].
Here we further characterized the 23 different scFvs to 
identify which ones reacted most strongly with ALS sam-
ples and to highlight the wide diversity of TDP-43 vari-
ants present in human neurodegenerative disease cases. 
We previously demonstrated a simple capture ELISA that 
utilizes a phage-displayed detection antibody with sub-
femtomolar sensitivity in conjunction with capture scFvs 
similar to those examined here [28, 38]. Here we gener-
ated a phage based detection antibody against TDP-43 
for use in a capture ELISA in conjunction with the 23 
scFvs (Stages 1B and 2 from Additional file  1: Fig. S1) 
to analyze sporadic ALS, c9orf72 ALS, FTD and control 
human samples (Stage 3 from Additional file 1: Fig. S1).
Results
Selection of detection phage for capture ELISA
To obtain a detection scFv that binds to all TDP-43 vari-
ants including healthy and disease related species, we 
performed a series of AFM based negative and positive 
biopanning procedures. We first removed phages that 
bound off-target antigens including bovine serum album 
(BSA) and aggregated synthetic alpha-synuclein. We then 
performed sequential rounds of positive panning using 
TDP-43 immunoprecipitated from the motor cortex of 
healthy, ALS and FTD human brain tissue (Fig.  1). Fol-
lowing positive panning on a mica substrate containing 
TDP-43 immunoprecipitated from healthy brain tissue, 
bound phages were eluted and then added to mica coated 
with TDP-43 immunoprecipitated from ALS tissue. Fol-
lowing elution from the ALS tissue, the recovered phages 
were added to mica coated with TDP-43 immunoprecipi-
tated from FTD tissue and eluted phage recovered. The 
recovered phage should bind healthy and disease variants 
of TDP-43 and were sequenced to verify the integrity of 
their DNA sequences.
We utilized indirect phage ELISAs to determine how 
well three of the different phages (TDPM1, TDPM2 
and TDPM3) would bind to brain tissue samples from 
ALS, FTD and control cases (Fig.  2a–c) and compared 
the results with that obtained using a commercially 
acquired anti-TDP-43 antibody (Fig.  2d and Stage 2 
from Additional file 1: Fig. S1). The TDPM1 phage most 
closely matched the binding of the control antibody in 
the phage ELISAs (Fig. 2a) so we selected this clone for 
use as the TDP-43 detection antibody in further analy-
ses. We also verified that the TDPM1 phage worked as 
a detection antibody in a capture ELISA. We randomly 
selected five of the previously isolated scFvs against ALS 
TDP-43 variants (ALS-TDP6, ALS-TDP13, ALS-TDP15, 
ALS-TDP18 and AD-TDP3) for use as capture antibod-
ies to assay TDP-43 immunoprecipitated from ALS, FTD 
and control tissue samples (Fig.  3a) and homogenized 
human brain tissue instead of immunoprecipitated pro-
teins (Fig. 3b). Using TDPM1 as the detection phage, all 
five scFvs showed strong reactivity with the ALS samples 
compared to the FTD and control samples (Fig. 3a, b).
Binding specificities of the anti‑TDP‑43 phages
Phage expressing the different anti-TDP-43 scFvs were 
previously selected for preferential binding to ALS brain 
tissue samples relative to both control and FTD cases as 
described [32]. We characterized the binding of 23 differ-
ent phage-displayed scFvs toward ALS, FTD and healthy 
human brain tissue samples from the motor cortex using 
a simple indirect phage ELISA (Additional file 1: Fig. S1, 
Stage 2). The scFv clones were re-labeled in the current 
study to facilitate identification and simplify discussion. 
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All scFvs were expressed in cell supernatant (Additional 
file 2: Fig. S2) and had stronger binding to ALS compared 
to both FTD and control samples (Additional file 3: Fig. 
S3) confirming the efficiency of our previously described 
biopanning protocol for generating reagents that bind 
disease specific protein variants [32].
Recognition of multiple TDP‑43 variants
We next determined if the scFvs isolated from the ALS 
biopanning process were binding distinct or similar or 
overlapping epitopes. We performed competition ELISAs 
utilizing the same five scFvs randomly selected previously 
(ALS-TDP6, ALS-TDP13, ALS-TDP15, ALS-TDP18 and 
AD-TDP3). Addition of competing scFvs did not signifi-
cantly reduce the detection signal indicating that the five 
scFvs all bind separate epitopes (Fig. 4a–e). While we did 
not perform competition ELISAs with all 23 scFvs, based 
on the competition ELISA results obtained with these 
five scFvs (Fig. 4a–e) and the different binding intensities 
of the 23 phages (Additional file 3: Fig. S3), it is likely that 
an array of different ALS associated TDP-43 epitopes are 
recognized by the different scFvs.
Selection of individual ALS cases utilizing human brain 
tissue
While the previous studies utilized pooled aliquots to 
conserve limited sample availability, selection of scFvs 
that bind all or different sets of ALS cases would be 
beneficial for biomarker analysis. To study individual 
ALS cases we first purified each of the scFvs using Ni–
NTA columns (Additional file  4: Fig. S4) and then ana-
lyzed 5 ALS and 5 control homogenized brain samples 
Fig. 1 Schematic illustrating biopanning protocol to generate generic TDP-43 detection phages. To isolate detection phages that bind all healthy 
and disease related TDP-43 variants, we first eliminated all phage particles that bind non-desired targets including BSA and aggregated alpha-synu-
clein using immunotubes. Next, in the positive biopanning phase, the remaining phage particles were added to a mica surface containing TDP-43 
immunoprecipitated from the motor cortex of healthy brain tissue. Any bound phages were glycine eluted and added to a mica surface with TDP-
43 immunoprecipitated from ALS brain tissue. Following glycine elution the same manner of positive panning was repeated for TDP-43 immuno-
precipitated from FTD brain tissue. Eluted phages were sequenced to verify scFv integrity and larger batches of each produced for further analysis
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individually. Results from 12 scFvs yielding the strongest 
reactivity with the individual samples are shown (Fig. 5a–
l) where the results are represented as number of stand-
ard deviations relative to the controls. As expected, all 12 
scFvs had significantly greater binding preference for ALS 
relative to the controls (Fig. 5a–l). The reactivity of each 
sample with each scFv is shown (Additional file 5: Table 
S1) where each plus sign indicates an additional one 
standard deviation increase from the mean of the con-
trol (only sample with more than 2SD were highlighted). 
Three scFvs (ALS-TDP6, ALS-TDP10 and ALS-TDP14) 
reacted with all 5 ALS samples, five (ALS-TDP4, ALS-
TDP5, ALS-TDP9, ALS-TDP15 and AD-TDP3) reacted 
with 4 of the 5 ALS samples and four (ALS-TDP11, ALS-
TDP13, ALS-TDP20 and AD-TDP1) reacted with 3 of 
the 5 ALS cases. While each scFv showed different bind-
ing specificity to the different ALS samples, none of the 
scFvs reacted with any of the control samples. Because 
the binding profiles of the scFvs with the different ALS 
cases varied, this provides further support that the differ-
ent scFvs bind distinct TDP-43 antigens.
Selection of individual ALS cases utilizing human plasma
Since the scFvs isolated against TDP-43 variants selec-
tively present in human ALS but not healthy brain tis-
sue could distinguish between ALS and control brain 
tissue samples, we next determined if any of the scFvs 
could also distinguish amongst sporadic ALS, c9orf72 
ALS and control plasma samples. Here we tested indi-
vidual plasma samples from 4 sporadic ALS cases, 4 ALS 
c9orf72 cases and 3 controls. Results from the nine scFvs 
that produced significant differences between the spo-
radic ALS and control plasma cases are shown (Fig. 6a–i). 
Five of the nine scFvs (ALS-TDP3, ALS-TDP6, ALS-
TDP7, ALS-TDP17 and ALS-TDP2) also produced statis-
tical differences between the sporadic ALS samples and 
the c9orf72 ALS cases. While most of the scFvs showed 
lower binding with the c9orf72 ALS samples compared to 
Fig. 2 Selection of generic TDP-43 binding detection phages. Binding of selected phages with homogenized ALS, FTD and healthy control (HT) 
brain tissue from the motor cortex was tested in indirect phage ELISAs using three of the potential detection phages and a commercial anti-TDP-43 
antibody. The TDP-43 binding patterns with a TDPM1, b TDPM2, c TDPM3 and d the commercial anti-TDP-43 antibody were all similar. TDPM1’s 
reactivity with all three groups seemed the closest to the commercial anti-TDP-43 antibody. Binding signals were represented relative to FTD. Bound 
phages were detected with an anti-M13-HRP antibody in these indirect ELISAs
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the sporadic ALS samples, the ALS-TDP10 scFv was the 
only scFv that also showed significantly higher reactivity 
with the c9orf72 ALS samples compared to the control 
group (Fig. 6e). The strength of the signals obtained with 
each of the scFvs toward each sample is shown where the 
first “+” indicates more than 1.5 SD increase from mean 
of the controls and each additional “+” sign indicating 
an additional 1 SD increase (Additional file 6: Table S2). 
While all 9 scFvs reacted with each of the 4 sporadic ALS 
plasma samples but none of the controls, the binding pro-
file with the c9orf72 ALS cases varied between scFvs. For 
example, two of the scFvs (ALS-TDP7 and ALS-TDP10) 
reacted with 3 of the 4 c9orf72 ALS cases, 4 of the scFvs 
(ALS-TDP5, ALS-TDP6, ALS-TDP11, ALS-TDP17) 
reacted with 2 of the 4 c9orf72 ALS cases, while 2 (ALS-
TDP15 and AD-TDP2) reacted with 1 of the 4 c9orf72 
ALS cases, although not the same one. ALS-TDP3 did 
not produce strong reactivity with any of the c9orf72 ALS 
cases. This variation in binding intensities and sample 
selection again supports a difference in target recognition 
between the scFvs. Additionally, ALS-TDP5, ALS-TDP6, 
ALS-TDP10, ALS-TDP11 and ALS-TDP15 produced the 
best results with both the individually tested ALS brain 
tissue and plasma cases (Additional file 5: Table S1, Addi-
tional file 6: Table S2) indicating their potential value as 
biomarkers for ALS.
Discussion
While TDP-43 pathology is present in the vast majority 
of examined ALS cases [1, 3–6, 9, 10, 39], the confor-
mation and location of the TDP-43 aggregates can vary, 
including oligomeric, truncated, phosphorylated and 
ubiquitinated configurations [12, 13]. Isolation of rea-
gents that can selectively recognize disease relevant TDP-
43 variants could facilitate diagnosis of ALS, particularly 
if these variants could be detected in blood based sam-
ples during early even pre-symptomatic stages of disease 
progression [40–42]. We previously isolated scFvs with 
preferential reactivity for TDP-43 immunoprecipitated 
from ALS human brain tissue relative to TDP-43 immu-
noprecipitated from healthy and FTD human brain tissue 
using our AFM based biopanning procedures [32]. Here 
we further identify a subset of these scFvs with diverse 
binding specificities that have potential applications to 
detect blood-based biomarkers for ALS.
We previously identified 23 distinct valid scFv 
sequences from the ALS TDP-43 positive biopanning 
and all showed preferential reactivity for homogenized 
human ALS brain tissue samples compared to FTD and 
control cases (Additional file 3: Fig. S3). We also gener-
ated a phage-displayed scFv that binds all forms of TDP-
43 including ALS, FTD and healthy variants (Fig. 2a) to 
be utilized in our capture ELISA protocol. We applied 
competition ELISAs to show that the different scFvs gen-
erated against the ALS relevant TDP-43 variants were 
binding different epitopes (Fig.  4a–e). Binding intensity 
variations between all 23 phages in the indirect phage 
ELISAs (Additional file 3: Fig. S3) also suggest the pres-
ence of multiple TDP-43 variants in ALS.
Using the scFvs in a capture ELISA format, we showed 
that 12 of the scFvs can statistically distinguish between 
ALS and healthy human brain tissue samples (Fig. 5a–l). 
By plotting signal strength as a function of number of 
standard deviations from the control, we showed that 
three of the scFvs (ALS-TDP6, ALS-TDP10 and ALS-
TDP14) reacted with all five ALS samples studied but 
none of the controls, while the nine other scFvs selected 
different combinations of 3–4 of the ALS cases and again 
none of the controls (Additional file  5: Table S1). The 
Fig. 3 Validation of detection phage using capture ELISA with scFvs 
selective for ALS TDP-43 variants. Soluble antibody fragments from 
5 (ALS-TDP6, ALS-TDP13, ALS-TDP15, ALS-TDP18 and AD-TDP3) of 
the 23 scFvs were produced and utilized as the capture scFvs in our 
phage capture ELISA. a TDP-43 immunoprecipitated from ALS, FTD 
and healthy brain tissue (motor cortex) was the antigenic source 
and bound antigens were detected using TDPM1. The results were 
represented as a difference between the ALS and both the FTD and 
control groups. TDPM1 produced strong signals with all 5 scFvs. b In 
a similar manner, substitution of brain tissue for the immunoprecipi-
tated protein with all five capture scFvs and TDPM1 showed positive 
signals with ALS relative to both FTD and healthy tissue. Bound 
phages were detected with an anti-M13-HRP antibody in these 
capture ELISAs
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variation in signal intensities for each sample suggests 
that the different targeted TDP-43 variants are present at 
different concentrations in the ALS cases. We have previ-
ously illustrated successful identification of AD and PD 
sera cases using multiple scFvs [28] and expect that such 
an approach can also be used for diagnosis of ALS.
To determine their potential diagnostic value, we ana-
lyzed plasma samples from 4 sporadic ALS cases, 4 
c9orf72 ALS cases and 3 controls using the anti-TDP-43 
scFvs and identified 9 promising scFvs. All 9 of the scFvs 
reacted with all 4 sporadic ALS cases (Additional file 6: 
Table S2). ALS-TDP7 and ALS-TDP10 selected 3 of the 
4 c9orf72 ALS cases, 6 of the 9 scFvs recognized 1–2 of 
the c9orf72 ALS cases and ALS-TDP3 did not select any 
of the c9orf72 ALS cases. Since the panning protocols 
included exhaustive negative panning against healthy 
control human samples, as expected, none of the scFvs 
reacted with any of the control samples. Since more than 
23 scFvs were generated from the TDP-43 panning pro-
cess, it is possible that screening some of the additional 
remaining scFvs will identify antibody fragments that 
select all of the c9orf72 ALS cases. Since plasma samples 
from different patients show different reactive profiles 
with the panel of anti-TDP scFvs, each patient may likely 
have their own personal biomarker profile corresponding 
to subtly different types of ALS. Utilizing a combination 
of multiple anti-TDP-43 scFvs may prove valuable in pro-
viding a personalized diagnosis for each patient in both 
sporadic and familial ALS cases. A personalized blood-
based diagnosis system could also be very helpful for ini-
tiating and monitoring treatment strategies for ALS [41, 
42].
Here we characterize the binding specificities of a sub-
set of 23 anti-TDP-43 scFvs we previously generated 
[32] with both human brain tissue and plasma samples 
to illustrate their preferential reactivity with ALS. The 
scFvs generated by selectively biopanning for TDP-43 
variants present in ALS but not FTD brain tissue do pref-
erentially bind ALS compared to both FTD and control 
samples. These results further support the proficiency 
Fig. 4 Competition ELISAs to test for overlapping epitopes recognized by the scFvs binding ALS selective TDP-43 variants. Competition capture ELI-
SAs were utilized to determine if the scFvs bound similar epitopes. Samples of homogenized ALS, FTD and healthy brain tissue (motor cortex) were 
pre-incubated with the ALS-TDP6, ALS-TDP13, ALS-TDP15, ALS-TDP18 and AD-TDP3 scFvs individually for ~1 h. These samples were then utilized 
in capture ELISAs with the same five scFvs immobilized to the wells: a ALS-TDP6, b ALS-TDP13, c ALS-TDP15, d ALS-TDP18 and e AD-TDP3. Bound 
phages were detected with an anti-M13-HRP antibody and signal intensities calculated based on the difference between the ALS and FTD samples. 
All the scFvs produced similar binding signal strengths with or without the presence of the competitive scFvs. One-way ANOVA with LSD post hoc 
analysis supported the competitor scFvs’ inability to block the recognized antigenic site of our capture scFvs since no significant differences were 
detected between its presence and the no competition sample. Overall, these results demonstrated recognition of multiple TDP-43 variants by our 
scFvs
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of our biopanning process at isolating reagents reac-
tive with target variants of interest. In future studies we 
intend to screen plasma from larger ALS and FTD sam-
ple sets to reaffirm which scFvs are ALS specific and if 
any also cross-react with FTD samples. Also, since TDP-
43 pathology is not unique to ALS and FTD, but has 
been detected in other neurodegenerative disease includ-
ing ~ 57% of individuals with AD, 19% of PD cases, 45% 
of individuals having dementia with Lewy bodies (DLB) 
and 100% of tested Huntington’s cases [12, 13, 39, 43–47], 
we also intend to screen the scFvs for cross reactivity with 
these other diseases. If scFvs can selectively bind specific 
disease cases, they may be useful reagents along with rea-
gents to other protein variants including beta-amyloid, 
alpha-synuclein and tau to help improve diagnosis of dif-
ferent neurodegenerative diseases [48].
We have previously shown that scFvs against alpha-
synuclein variants associated with Parkinson’s disease 
have excellent therapeutic value [49, 50]. In a similar 
fashion, since our scFvs selectively bind ALS associated 
variants of TDP-43, in addition to diagnostic value, the 
scFvs may also have potential therapeutic value.
Conclusion
Our TDP-43 reactive scFvs were selective for individ-
ual ALS cases relative to controls utilizing both human 
brain tissue and plasma samples. The scFvs recognized 
both sporadic and familial ALS cases with plasma. 
Fig. 5 Characterization of individual ALS brain tissue samples with the different scFvs. Assessment of the binding specificities of the scFvs with 
brain tissue (motor cortex) from 5 individual ALS cases and 5 controls (as opposed to with pooled samples used in past studies). Results with the 
12 most reactive scFvs are shown: a ALS-TDP4, b ALS-TDP5, c ALS-TDP6, d ALS-TDP9, e ALS-TDP10, f ALS-TDP11, g ALS-TDP13, h ALS-TDP14, i 
ALS-TDP15, j ALS-TDP20, k AD-TDP1 and l AD-TDP3. Here we utilized a biotinylated TDP-43 phage capture ELISA system to enhance our detection 
capabilities. On average, all 12 scFvs showed significantly greater reactivity with the 5 ALS brain tissue samples compared to the controls. Statistical 
significance is based on one-way ANOVA with LSD post hoc analysis at p < 0.05. Signal intensities are based on the number of standard deviations 
each sample is from the controls. This is calculated by subtracting the mean of the controls from each sample and then dividing the result by the 
SD of the controls
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These results support the potential diagnostic value of 
our TDP-43 scFvs when employed in our phage capture 
ELISA system.
Methods
Human samples
ALS, FTD and healthy human brain tissue samples from 
the motor cortex and immunoprecipitated TDP-43 pro-
teins from these cases were provided from the George-
town Brain Bank (Georgetown University Medical 
Center) and New York Brain Bank (Columbia Univer-
sity). Patient age and gender for these samples are pro-
vided in Table 1. All samples were provided de-identified 
with regard to patient identifiable information, and all 
tissue/biofluid banks are operating under institutional 
IRB guidelines. Plasma samples from ALS, c9orf72 ALS 
and healthy human cases were provided by Dr. John 
Ravits (University of California, San Diego School of 
Medicine) and collected by an Investigational Review 
Board-compliant process. Patient age and gender for 
these samples are provided in Table 1.
Phage production
To produce phage particles from the ALS TDP-43 clones 
isolated earlier, we essentially follow the previously 
described protocol (http://www.lifesciences.sourcebio-
science.com/media/143421/tomlinsonij.pdf ) [28, 32, 38]. 
E. coli TG1 cells containing the plasmids for our clones 
Fig. 6 Characterization of individual ALS plasma samples with the different scFvs. Human plasma samples from 4 sporadic ALS cases, 4 c9orf72 
ALS cases and 3 healthy control cases were assayed for the presence of TDP-43 variants. Results of the 9 most reactive scFvs are shown: a ALS-TDP3, 
b ALS-TDP5, c ALS-TDP6, d ALS-TDP7, e ALS-TDP10, f ALS-TDP11, g ALS-TDP15, h ALS-TDP17 and i AD-TDP2. A biotinylated TDP-43 phage capture 
ELISA system was utilized to enhance our detection capabilities. On average, all the scFvs showed significantly greater reactivity with the sporadic 
ALS cases relative to the controls. ScFvs ALS-TDP3, ALS-TDP6, ALS-TDP7, ALS-TDP17 and AD-TDP2 also showed statistical differences between 
the sporadic ALS cases and the c9orf72 ALS samples. In addition, ALS-TDP10 could significantly distinguish between the c9orf72 ALS and control 
groups. Statistical significance is based on one-way ANOVA with LSD post hoc analysis at p < 0.05. Signal intensities are based on the number of 
standard deviations each sample is from the controls. This is calculated by subtracting the mean of the controls from each sample and then dividing 
the result by the SD of the controls
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were cultured in 2xYT containing 100  μg/ml ampicillin 
and 1% glucose until OD600 was 0.4–0.6. The cells were 
then incubated with 2  ×  1011 of KM13 helper phage 
or hyperphage (Progen, Germany) for 30  min without 
shaking, followed by media exchange to 2xYT contain-
ing 100 μg/ml ampicillin, 50 μg/ml kanamycin and 0.1% 
glucose post centrifugation. The cells were then cultured 
overnight at 30  °C, followed by centrifugation to isolate 
the supernatant. Polyethylene glycol (PEG)/NaCl was 
added to the supernatant and it incubated on ice for 1 h. 
The mixture was then centrifuged and the pellet resus-
pended in PBS. Following another 1 h incubation on ice, 
additional cell debris was removed via a last centrifuga-
tion step. Their concentrations were estimated using a 
bicinchoninic acid (BCA) assay (Pierce, USA) and stored 
at −80 °C.
Biopanning for anti‑TDP‑43 detection antibody
For the capture ELISA utilized here we require a detec-
tion scFv that recognizes all forms of the target antigen, 
in this case TDP-43. The detection scFv is displayed on 
the phage surface generating essentially a self-assem-
bling nanoparticle for detection. The detection antibody 
should bind multiple forms, conformations and vari-
ants of the target TDP-43 antigen. To acquire the detec-
tion antibody, we utilized our previously described AFM 
based biopanning protocols [32]. We utilized a combina-
tion of three different scFv libraries including the Tomlin-
son I and J libraries and Sheets library [51] as our initial 
scFv pool. A series of negative panning steps were then 
completed to remove phage binding non-desired targets 
including bovine serum albumin (BSA) and aggregated 
synthetic alpha-synuclein (Fig. 1). We then performed a 
positive panning step using an aliquot of TDP-43 immu-
noprecipitated from the motor cortex of healthy human 
brain tissue deposited on a mica substrate (Fig. 1). Bound 
phages were eluted with glycine and added to a second 
piece of mica containing an aliquot of TDP-43 immu-
noprecipitated from ALS human brain tissue. Following 
glycine elution, phages were then added to a third piece 
of mica containing an aliquot of TDP-43 immunopre-
cipitated from FTD human brain tissue. Bound phages 
were again eluted with glycine and recovered by infec-
tion of TG1 cells. We utilized multiple rounds of positive 
panning with TDP-43 immunoprecipitated from diverse 
brain homogenate samples to ensure selection of a detec-
tion antibody that is reactive with normal and disease 
associated forms of TDP-43. Eluted phages were then 
screened using phage ELISAs and the integrity of their 
DNA sequences verified (Stage 2 from Additional file 1: 
Fig. S1). Plasmid isolation was accomplished using the 
Qiagen Miniprep Kit (Valencia, CA, USA). The selected 
TDP-43 detection phage was then biotinylated using the 
EZ-Link Pentylamine-Biotinylation kit (Thermo Scien-
tific, USA) as previously described [38] for use in the cap-
ture ELISA.
Indirect ELISAs
Indirect ELISA and tissue homogenization were per-
formed as described previously [28, 32, 38]. Briefly, 
2–10  μg/ml of homogenized human brain tissue was 
added to a 96-well ELISA plate and incubated for 1 h at 
37 °C. Following three washes with 0.1% PBS-Tween 20, 
non-specific binding sites were blocked with 2% milk in 
PBS. Either a 1/100 dilution of phage particles or 1/1000 
of rabbit anti-TDP-43 antibody (ProteinTech, IL, USA) 
was added to the wells followed by anti-M13 HRP (GE 
Healthcare Life Science, NJ, USA) or goat anti-rabbit IgG 
HRP (Santa Cruz Biotechnology, Texas, USA), respec-
tively. Enzyme detection was achieved using the Super-
Signal ELISA Femto Maximum Sensitivity Substrate kit 
(Thermo Scientific, USA) and signal intensities quanti-
fied using the Perkin Elmer Wallac 1420 Victor2 Multi-
label Counter.
Table 1 Patient cohort demographics
BT brain tissue, P plasma
Cases Age Gender Sample type
ALS-1 88 F BT
ALS-2 60 M BT
ALS-3 73 M BT
ALS-4 45 M BT
ALS-5 64 M BT
FTD-1 80 M BT
FTD-2 66 M BT
FTD-3 67 F BT
FTD-4 74 M BT
FTD-5 68 M BT
C-1 79 M BT
C-2 90 M BT
C-3 41 M BT
C-4 60 M BT
C-5 72 M BT
SALS-1 58 M P
SALS-2 38 M P
SALS-3 58 F P
SALS-4 46 M P
c9orf72-1 73 M P
c9orf72-2 61 M P
c9orf72-3 58 F P
c9orf72-4 67 F P
C-1 62 M P
C-2 50 M P
C-3 41 F P
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ScFv production and purification
ScFvs were expressed and purified as previously described 
[28, 32, 38]. Briefly, HB2151 cells were cultured for 2–3 h 
at 37 °C in 2xYT, 0.1% glucose and ampicillin until OD600 
was 0.4. Isopropyl β-d-1-thiogalactopyranoside (IPTG) 
was then added and the temperature reduced to 30  °C. 
The following day the supernatant was harvested and 
stored at −20  °C. Purification was completed under 
native conditions by incubating the supernatant with Ni–
NTA agarose beads (Qiagen, CA, USA) for 1–2 h at 4 °C. 
The mixture was then transferred to a column. Following 
washing, bound scFvs were eluted using a 250 mM imi-
dazole solution. Dot and Western blotting analyses were 
used to confirm expression and purification using the 
C-Terminal c-myc tag on our scFvs.
Phage capture ELISAs
Phage capture ELISAs were performed essentially as 
described previously [38]. Briefly, unconcentrated super-
natant containing the scFvs or Ni–NTA purified scFvs 
was added to the wells of high binding ELISA plates for 
1 h at 37 °C on a shaker. All incubations were performed 
at 37  °C whilst shaking. After washing with 0.1% PBST 
three times, the wells were blocked with 2% milk in PBS. 
Next, human brain tissue (2–10 μg/ml) or sera (1/100 
v/v) was added followed by 200  ng/ml of the 40  mmol 
carboxyl biotinylated phage. After addition of the sec-
ondary antibody avidin-HRP (Sigma-Aldrich, USA), 
enzyme detection was again achieved using the SuperSig-
nal ELISA Femto Maximum Sensitivity Substrate kit.
When screening the potential detection phage using 
the capture ELISA system, the phage was not bioti-
nylated and therefore detected using the anti-M13 HRP 
antibody. Similarly, any reactivity with the commercial 
anti-TDP-43 antibody was recognized with the goat anti-
rabbit IgG HRP secondary. Lastly, the quantity of immu-
noprecipitated proteins utilized in these ELISAs was 
20 ng.
Competition ELISAs
Competition ELISAs were carried out using the phage 
capture ELISA protocol except preceding addition of the 
brain tissue, the samples were pre-incubated with the dif-
ferent competitive scFvs for ~1 h.
Statistical analysis
The ratio of each sample reading to the value obtained 
for PBS was first calculated. The mean of the control 
and/or FTD cases was then subtracted from each sam-
ple. This type of calculation was utilized due to the dif-
ficulty in acquiring large purified quantities of the targets 
recognized by our scFvs in order to generate a stand-
ard curve to quantify the reactivity of each sample. We 
evaluated the reactivity of the test sample relative to the 
average signal intensity of the control and/or FTD groups 
by subtracting their average reactivity from that of the 
ALS group thus setting control values to zero. Statistical 
significance was calculated using one-way ANOVA and 
LSD Post-Hoc analyses with significance at p < 0.05. The 
graphs and statistical analyses were completed using the 
IBM SPSS Statistics 23 program. In Figs. 5 and 6, to illus-
trate the intensity difference between the test and control 
groups, we plotted the number of standard deviations 
each sample was from the controls by subtracting the 
mean of the controls from each sample and dividing the 
result by the standard deviation of the controls. In Addi-
tional file 5: Table S1, Additional file 6: Table S2, the level 
of activity was further highlighted using a “+” sign sys-
tem. In Additional file 5: Table S1 each “+” sign indicated 
one standard deviation (SD) increase relative to the mean 
of the controls. In Additional file 6: Table S2 the first “+” 
indicated a 1.5 SD increase followed by each additional 
“+” sign indicating another 1 SD increase. Furthermore, 
since brain tissue homogenization was conducted at dif-
ferent intervals, technique variation was accounted for in 
the ELISAs by first dividing by matching controls.
Additional files
Additional file 1: Figure S1. Schematic of the Development of our 
Biotinylated TDP-43 Phage Capture ELISA System. A schematic of the 
entire process utilized to develop our biotinylated TDP-43 phage-capture 
ELISA system for heightened detection of TDP-43 variants is shown. Stage 
1A—Previously described AFM based negative and positive biopanning 
protocol to isolate the capture scFvs reactive with TDP-43 variants isolated 
from ALS brain tissue [32]. Starting with an initial scFv library, we first elimi-
nated scFvs reactive with undesired targets including BSA, aggregated 
alpha-synuclein and healthy human brain tissue using immunotubes. 
AFM analysis was utilized to monitor the process. We next completed 
negative panning against TDP-43 immunoprecipitated from healthy and 
FTD brain tissue (motor cortex) using a mica surface to conserve limited 
sample availability. The remaining phages were then utilized in positive 
biopanning against TDP-43 immunoprecipitated from ALS brain tissue. 
Any eluted phages following this process should be specific for ALS 
related TDP-43 variants. Stage 1B—To isolate a detection phage that is 
reactive with all forms of TDP-43 we utilized the AFM biopanning process 
described in Fig. 1. Stage 2—Both the potential ALS TDP-43 reactive 
phages isolated in the previous study and the detection phages acquired 
in the current study were first screened in indirect ELISAs against ALS, 
FTD and healthy brain tissue. Any bound phage particles were detected 
with an anti-M13-HRP secondary antibody. ALS TDP-43 specific phages 
should generate signals only in the wells containing ALS tissue, whilst the 
detection phages should produce signals with all three tissue types. Stage 
3 - Finally, following biotinylation of the 2700 coat protein on our detec-
tion phage to heighten our sensitivity, our complete phage capture ELISA 
system was used to analyze individual human brain tissue and plasma 
samples. Some of the utilized illustrations were adapted from previously 
published graphics [32, 38].
Additional file 2: Figure S2. Expression of Soluble Antibody Fragments. 
Soluble antibody fragments from 17 of the 23 scFvs were produced and 
secreted into the supernatant as confirmed by dot blot analysis using an 
anti-c-myc antibody to label the scFvs. A scFv reactive with phosphorylase 
B was included as a positive control in the assay.
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Abbreviations
ALS: amyotrophic lateral sclerosis; AFM: atomic force microscopy; FTD: fronto-
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